Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marty Mullins

Physician Assistant Hazard, KY Physician Assistant

NPI 1699778795 CMS profile 10908635

210 Black Gold Blvd Ste 106, Hazard, KY 41701

Open in the dashboard

General payments

$63,478

243 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marty Mullins of Hazard, KY is reported in the CMS Open Payments database as having received $63,478 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,837 21
2024 General $6,120 33
2023 General $1,037 30
2022 General $15,392 53
2021 General $33,092 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marty Mullins
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Marty Mullins were reported at $7,837. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Marty Mullins Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $33,092 $132 $37–$438 $132
2022 $15,392 $155 $48–$522 $149
2023 $1,037 $167 $52–$557 $160
2024 $6,120 $178 $55–$600 $164
2025 $7,837 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Esperion Therapeutics, Inc. $47,330 85 payments
  2. Amgen Inc. $13,511 37 payments
  3. Kowa Pharmaceuticals America, Inc. $517 2 payments
  4. Gilead Sciences, Inc. $377 17 payments
  5. AbbVie, Inc. $358 19 payments
  6. Janssen Pharmaceuticals, Inc $255 19 payments
  7. Dexcom, Inc. $183 5 payments
  8. Novo Nordisk Inc $151 9 payments
  9. Biohaven Pharmaceuticals, Inc. $122 8 payments
  10. Daiichi Sankyo Inc. $108 7 payments
  11. Other $566 35 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,506 44 payments
  2. Food and Beverage $4,263 170 payments
  3. Travel and Lodging $3,208 28 payments
  4. Consulting Fee $500 1 payment
Products named General payments · program years 2021–2025
  1. NEXLETOL $47,330 85 payments
  2. NEXLIZET $47,206 78 payments
  3. REPATHA Cardiovascular $7,644 16 payments
  4. Repatha Cardiology $5,808 17 payments
  5. MAVYRET $238 10 payments
  6. XARELTO $235 18 payments
  7. NURTEC ODT $172 11 payments
  8. Ozempic $151 9 payments
  9. RYBELSUS $139 8 payments
  10. INJECTAFER $108 7 payments
  11. Other $1,210 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

4,172

Median for Physician Assistant: 241

Drug cost

$420,343

Median for Physician Assistant: $4,110

Branded share of claims

19.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 85 $72,094
Mounjaro Tirzepatide Brand 56 $67,494
Ozempic Semaglutide Brand 44 $42,077
Farxiga Dapagliflozin Propanediol Brand 42 $41,307
Jardiance Empagliflozin Brand 47 $35,814
Tradjenta Linagliptin Brand 33 $20,907
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 23 $16,687
Januvia Sitagliptin Phosphate Brand 12 $14,805
Xarelto Rivaroxaban Brand 12 $14,348
Trulicity Dulaglutide Brand 14 $12,613

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $5,714
$5,714 20 —
BESREMI
  • PharmaEssentia USA Corporation $30
$30 — —
VRAYLAR
  • AbbVie, Inc. $29
$29 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $19
$19 12 —
BEXSERO
  • GlaxoSmithKline, LLC. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record